Cancer

Cancer Research Institute

Clinical Trials

Showing 1-9 out of 125 results.
NCT05629585

: D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)

Icon for trial | D926XC00001 : D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disea

This study is currently enrolling.

We are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug called durvalumab, will work and ...

NCT06132958

: MK2870-005/ENGOT-en23/GOG3095 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy

Icon for trial | MK2870-005/ENGOT-en23/GOG3095 : MK2870-005/ENGOT-en23/GOG3095 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants Wi

This study is currently enrolling.

The purpose of this trial is to: Test the safety of the trial drug, MK-2780: see how well the trial drug works, see how your body handles the trial drug. See how well MK-2870 works compared to the 2 standard chemotherapies. See ...

NCT06016738

: OP-1250-301 A Phase 3 Randomized Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01)

Icon for trial | OP-1250-301 : OP-1250-301 A Phase 3 Randomized Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01)

This study is currently enrolling.

The goal of this study is to test if the study drug, OP-1250, is better or worse than the usual approach for your type of breast cancer. The usual approach, also known as the “standard of care”, is defined as care most people ...